You are currently viewing a new version of our website. To view the old version click .
Molecules
  • Correction
  • Open Access

2 June 2022

Correction: Döring et al. Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy. Molecules 2021, 26, 18

,
,
and
1
Research Group of Drug Development, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany
2
Department of Clinical Pharmacy, Institute of Pharmacy, Ernst Moritz Arndt University Greifswald, 17489 Greifswald, Germany
*
Author to whom correspondence should be addressed.
The authors would like to correct an error made through no fault of their own in the title paper [1]. The error is related to the FAR values in Table 1. In the earlier published version, the FAR values of compounds 1521 were wrongly printed. So, they had to be corrected, from 1.19 to 1.12 for 15, 1.55 to 1.19 for 16, 0.95 to 1.55 for 17, 1.22 to 0.95 for 18, 0.98 to 1.22 for 19, 1.30 to 0.98 for 20 and 0.82 to 1.30 for 21. We provide below the corrected Table 1. The change has no influence on the reported results. The original article has been updated. The authors would like to apologize for any inconvenience caused to the readers by this change.
Table 1. MRP4 inhibition data of target compounds 421 with varied substitution patterns expressed as FAR values.

Reference

  1. Döring, H.; Kreutzer, D.; Ritter, C.; Hilgeroth, A. Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy. Molecules 2021, 26, 18. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.